Stem Cell-Based Therapies for Liver Diseases: State of the Art and New Perspectives
Millions of patients worldwide suffer from end-stage liver pathologies, whose only curative therapy is liver transplantation (OLT). Given the donor organ shortage, alternatives to OLT have been evaluated, including cell therapies. Hepatocyte transplantation has been attempted to cure metabolic live...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2010-01-01
|
Series: | Stem Cells International |
Online Access: | http://dx.doi.org/10.4061/2010/259461 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832561030594560000 |
---|---|
author | Anna Chiara Piscaglia Mariachiara Campanale Antonio Gasbarrini Giovanni Gasbarrini |
author_facet | Anna Chiara Piscaglia Mariachiara Campanale Antonio Gasbarrini Giovanni Gasbarrini |
author_sort | Anna Chiara Piscaglia |
collection | DOAJ |
description | Millions of patients worldwide suffer from end-stage liver pathologies, whose only curative therapy is liver transplantation (OLT). Given the donor organ shortage, alternatives to OLT have been evaluated, including cell therapies. Hepatocyte transplantation has been attempted to cure metabolic liver disorders and end-stage liver diseases. The evaluation of its efficacy is complicated by the shortage of human hepatocytes and their difficult expansion and cryopreservation. Recent advances in cell biology have led to the concept of “regenerative medicine”, based on the therapeutic potential of stem cells (SCs). Different types of SCs are theoretically eligible for liver cell replacement. These include embryonic and fetal SCs, induced pluripotent cells, annex SCs, endogenous liver SCs, and extrahepatic adult SCs. Aim of this paper is to critically analyze the possible sources of SCs suitable for liver repopulation and the results of the clinical trials that have been published until now. |
format | Article |
id | doaj-art-8e29c75d9bde4861a9465e3a9d812f27 |
institution | Kabale University |
issn | 1687-9678 |
language | English |
publishDate | 2010-01-01 |
publisher | Wiley |
record_format | Article |
series | Stem Cells International |
spelling | doaj-art-8e29c75d9bde4861a9465e3a9d812f272025-02-03T01:26:07ZengWileyStem Cells International1687-96782010-01-01201010.4061/2010/259461259461Stem Cell-Based Therapies for Liver Diseases: State of the Art and New PerspectivesAnna Chiara Piscaglia0Mariachiara Campanale1Antonio Gasbarrini2Giovanni Gasbarrini3“Gastrointestinal and Liver Stem Cell Research Group” (GILSteR), Department of Internal Medicine, Gemelli Hospital, Catholic University of Rome, Largo A. Gemelli 8-00168 Roma, Italy“Gastrointestinal and Liver Stem Cell Research Group” (GILSteR), Department of Internal Medicine, Gemelli Hospital, Catholic University of Rome, Largo A. Gemelli 8-00168 Roma, Italy“Gastrointestinal and Liver Stem Cell Research Group” (GILSteR), Department of Internal Medicine, Gemelli Hospital, Catholic University of Rome, Largo A. Gemelli 8-00168 Roma, Italy“Gastrointestinal and Liver Stem Cell Research Group” (GILSteR), Department of Internal Medicine, Gemelli Hospital, Catholic University of Rome, Largo A. Gemelli 8-00168 Roma, ItalyMillions of patients worldwide suffer from end-stage liver pathologies, whose only curative therapy is liver transplantation (OLT). Given the donor organ shortage, alternatives to OLT have been evaluated, including cell therapies. Hepatocyte transplantation has been attempted to cure metabolic liver disorders and end-stage liver diseases. The evaluation of its efficacy is complicated by the shortage of human hepatocytes and their difficult expansion and cryopreservation. Recent advances in cell biology have led to the concept of “regenerative medicine”, based on the therapeutic potential of stem cells (SCs). Different types of SCs are theoretically eligible for liver cell replacement. These include embryonic and fetal SCs, induced pluripotent cells, annex SCs, endogenous liver SCs, and extrahepatic adult SCs. Aim of this paper is to critically analyze the possible sources of SCs suitable for liver repopulation and the results of the clinical trials that have been published until now.http://dx.doi.org/10.4061/2010/259461 |
spellingShingle | Anna Chiara Piscaglia Mariachiara Campanale Antonio Gasbarrini Giovanni Gasbarrini Stem Cell-Based Therapies for Liver Diseases: State of the Art and New Perspectives Stem Cells International |
title | Stem Cell-Based Therapies for Liver Diseases: State of the Art and New Perspectives |
title_full | Stem Cell-Based Therapies for Liver Diseases: State of the Art and New Perspectives |
title_fullStr | Stem Cell-Based Therapies for Liver Diseases: State of the Art and New Perspectives |
title_full_unstemmed | Stem Cell-Based Therapies for Liver Diseases: State of the Art and New Perspectives |
title_short | Stem Cell-Based Therapies for Liver Diseases: State of the Art and New Perspectives |
title_sort | stem cell based therapies for liver diseases state of the art and new perspectives |
url | http://dx.doi.org/10.4061/2010/259461 |
work_keys_str_mv | AT annachiarapiscaglia stemcellbasedtherapiesforliverdiseasesstateoftheartandnewperspectives AT mariachiaracampanale stemcellbasedtherapiesforliverdiseasesstateoftheartandnewperspectives AT antoniogasbarrini stemcellbasedtherapiesforliverdiseasesstateoftheartandnewperspectives AT giovannigasbarrini stemcellbasedtherapiesforliverdiseasesstateoftheartandnewperspectives |